Furthermore, mucin 1 (MUC1), overexpressed in select CCA cases, is under investigation as a potential therapeutic target, with several antibodies in the pipeline, including CanAg, cantuzumab mertansine, clivatuzumab tetraxetan, gatipotuzumab, pankomab, and pemtumomab [9,78,79,80,81,82]. Here, MUC1 is linked to cholangiocarcinoma.